Replies to post #161037 on Biotech Values

[DewDiligence]

BAX—Given how fashionable corporate split-ups have become, I’m surprised no one on Wall Street is lobbying BAX to spin off (or sell) its dialysis business or to go one step further and separate the hospital-supplies business from the pharma business.

Peritoneal dialysis is a simple process that doesn't actually require any branded products, just saline and a couple of peritoneal lines. Its been done for years with off the rack hospital products and is quite low tech.

Nonetheless, BAX logged $2.5B of sales from this business line in 2012, although there was no growth relative to 2011.